Psych Observer – Exposing Bad Psychiatry

Shane Ellison has a masters degree in organic chemistry and is a two-time recipient of the prestigious Howard Hughes Medical Institute Research Grant for his studies in biochemistry and physiology. Here Shane exposes the inner workings of the psycho/pharmaceutical industry, the manufacture and marketing of psychiatric drugs and the fact that the psycho/pharma industry is well aware their drugs do not cure anyone. He previously worked for both Array BioPharma and Eli Lilly.

[youtube]http://www.youtube.com/watch?v=fOT5DSIUTOY[/youtube]

By Jon Burstein
April 24, 2009

MARGATE – State officials are investigating whether a 7-year-old boy who hanged himself in his Margate foster home had been given a powerful, mind-altering drug in violation of Florida law.

Three weeks before his April 16 suicide, Gabriel Myers was prescribed the drug Symbyax, which is a combination of the generic forms of the anti-depressant Prozac and the anti-psychosis drug Zyprexa, according to state Department of Children & Families records released Friday night.

But there was no court order in place for Gabriel to use the drug, the records show. Under Florida law, parental consent or a judge’s ruling is needed before a foster child can be administered a psychotropic drug.

Read the rest…

The Winnendon, Germany school shooting, which left 17 dead including the gunman, appears to be the latest in the chain of psychiatric drug-induced school shootings. A March 15 article in Scotland on Sunday, revealed that the shooter, Tim Kretschmer, “had been suffering from depression, even attending a clinic and receiving medication for the condition.”

With casualties from school or teen shootings now totaling 54 dead and 105 wounded, the mental health watchdog Citizens Commission on Human Rights (CCHR) says it is time to stop vested interests from spouting their usual propaganda about psychiatric drugs, and instead demand a federal investigation for the sake of public safety.

Read the rest…

* Story Highlights
* Atypical antipsychotic drugs associated with higher risk of sudden cardiac death
* Atypicals were thought to be safer than older, so-called “typical” antipsychotics
* Three atypical antipsychotics are among the 10 top-selling drugs worldwide
* About 325,000 people in the U.S. die of sudden cardiac death each year

By Anne Harding

Susan Craig’s brother Roger died of a pulmonary embolism in 2007, at age 38. Diagnosed with bipolar disorder in high school, he had been on antipsychotic drugs for years. At the time of his death, he was carrying 280 pounds on his 6-foot-4-inch frame.

Craig, a public relations specialist who works at Columbia University in New York City, knew that Roger’s medications could cause weight gain. But she had never been told that the drugs he was taking might be harming his heart.

“We were never counseled by his psychiatrist or his primary care provider to watch for symptoms of heart disease or any risk of sudden death at all,” Craig says. There’s no evidence that Roger’s medications caused his death, but his family might have been able to get him help sooner if they had known about the risks, Craig explains.
Read the rest…

Addiction, violence and suicide – these are some of the thousands of risks of antidepressants, but you won’t hear about it from your doctor, because he doesn’t know.

Paxil, Zoloft, Effexor, Prozac – how effective are they? Does Big Pharma want you to know? Douglas Kennedy – Fox News.

The risk of suicide at least doubles for children taking antidepressants according to short-term clinical trials.

Antidepressants are compared by researchers to cocaine in the DSM lll.

[youtube]http://www.youtube.com/watch?v=1Bzwx5HcurM[/youtube]

[youtube]http://www.youtube.com/watch?v=Sstoa406Oa0[/youtube]

Nashville, TN, January 15: Atypical antipsychotics, a widely prescribed class of drugs that help combat psychiatric disorders like schizophrenia, autism and dementia, may actually double the patients’ risk of fatal heart attacks, just as the older drugs, a study has found.

The study conducted at the Vanderbilt University and the Nashville Veterans Affairs Medical Center analyzed Medicaid records (from 1990 to 2005) of nearly 277,000 people aged between 30 and 74 years. While one-third of the people were taking either a newer or an older version of the antipsychotics, two-thirds were nonusers.

For each antipsychotic drug user, two age and sex matched non-users were assessed. During follow-up period, 478 sudden cardiacdefine deaths occurred among those taking the drugs – twice the rate that occurred in the control group, researchers report.

Read the rest…

Submitted by DannyHaszard on August 22, 2008 – 12:33pm.

Eli Lilly sells a drug that can cause diabetes and then turn a profit on the drugs that treat the condition that they may have caused in the first place! Zyprexa is the product name for Olanzapine,it is Lilly’s top selling drug.It was approved by the FDA in 1996 ,an ‘atypical’ antipsychotic a newer class of drugs without the motor side effects of the older Thorazine.
Read the rest…

By Bruce E. Levine, AlterNet
Posted on July 23, 2008, Printed on July 24, 2008

American psychiatry has been rocked by Congress. Congressional investigators first exposed the financial relationships between high-profile psychiatrists and drug companies. “But now the profession itself is under attack in Congress,” reported the New York Times on July 12, 2008.

Specifically under attack is psychiatry’s premier professional organization, the American Psychiatric Association. The New York Times stated, “In 2006, the latest year for which numbers are available, the drug industry accounted for about 30 percent of the association’s $62.5 million in financing. About half of that money went to drug advertisements in psychiatric journals and exhibits at the annual meeting, and the other half to sponsor fellowships, conferences and industry symposiums at the annual meeting.”

Read the rest…

By Terry Date
Staff writer

Seventeen state representatives wrote New Hampshire Attorney General Kelly Ayotte in May, asking her to seek financial compensation from pharmaceutical companies that have improperly marketed or not fully disclosed side effects of antipsychotic drugs.

The petitioners didn’t know it at the time, but the attorney general’s office had been investigating one of those companies, Bristol-Myers Squibb, since 2004.

Read the rest…